We demonstrated that ERBB2 can be targeted and controlled with tumor death across many tissues and in diverse biological backgrounds, namely, in EGFR T790M lung cancer, in ERBB2+ wildtype breast cancer, in ERBB2+ trastuzumab-resistant breast, and in ERBB2-mutated lung cancer and ERBB2-expressing colorectal cancer. This evidence concerns the gene EGFR and breast cancer.